Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

被引：3
|
作者：
Phillips, Tycel [1 ]
Lugtenburg, Pieternella [2 ]
Kalsekar, Anupama [3 ]
Mutebi, Alex [3 ]
Wang, Anthony [4 ]
Blaedel, Julie [3 ]
Kosa, Katherine [5 ]
Martin, Susan [5 ]
Sacchi, Mariana [3 ]
Thieblemont, Catherine [6 ,7 ]
机构：
[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA
[2] Erasmus MC, Dept Hematol, HOVON Lymphoma Working Grp, Canc Inst,Univ Med Ctr, Rotterdam, Netherlands
[3] Genmab, Princeton, NJ USA
[4] AbbVie Inc, N Chicago, IL USA
[5] RTI Hlth Solut, Ann Arbor, MI USA
[6] Hop St Louis, AP HP, Paris, France
[7] Diderot Univ, Sorbonne Paris Cite, Paris, France
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159544
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8022 / 8023
页数：2
相关论文
共 50 条
  • [31] Epcoritamab plus GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
    Cordoba, Raul
    Jorgensen, Judit
    Belada, David
    Costello, Regis
    Trneny, Marek
    Vitolo, Umberto
    John Lewis, David
    Karimi, Yasmin H.
    Sureda, Anna
    Andre, Marc
    Wahlin, Bjorn E.
    Lugtenburg, Pieternella J.
    Jiang, Tony
    Abbas, Aqeel
    Song, Yaou
    Risum, Malene
    Brody, Joshua D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S468 - S469
  • [32] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
    Hess, G.
    Thieblemont, C.
    Clausen, M. R.
    Lugtenburg, P.
    Balari, Sureda A.
    Zinzani, P. L.
    Wu, J.
    Finn, L.
    Vindelov, S. D.
    Fox, C. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
  • [33] Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma
    Tsutsue, Saaya
    Makita, Shinichi
    Yi, Jingbo
    Crawford, Bruce
    FUTURE ONCOLOGY, 2021, 17 (33) : 4511 - 4525
  • [34] Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Li, Tommy
    Gibiansky, Leonid
    Parikh, Apurvasena
    Chiu, Christopher W.
    Sacchi, Mariana
    Feng, Huaibao
    Ahmadi, Tahi
    Gupta, Manish
    Xu, Steven
    BLOOD, 2023, 142
  • [35] Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
    Clausen, Michael Roost
    Lugtenburg, Pieternella
    Hutchings, Martin
    Johnson, Peter W. M.
    Linton, Kim M.
    Lewis, David John
    Chamuleau, Martine
    Balari, Anna Sureda
    Cunningham, David
    Elliott, Brian
    DeMarco, Dena
    Chen, Kuo-mei
    Mous, Rogier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma
    Meyer, Kellie
    Huang, Danmeng
    O'Day, Ken
    Lahue, Betsy J.
    Wang, Anthony
    Mutebi, Alex
    Brodkin, Samantha
    Jun, Monika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] A SYSTEMATIC REVIEW OF THE HEALTH-RELATED QUALITY OF LIFE AND COSTS IN DIFFUSE LARGE B-CELL LYMPHOMA
    Chadda, S.
    Nelson, L.
    Podlogar, S.
    Garside, J.
    Upton, C. M.
    VALUE IN HEALTH, 2017, 20 (09) : A430 - A430
  • [38] Health-Related Quality of Life in Older Patients Following Diffuse Large B-Cell Lymphoma (DLBCL) Diagnosis
    Kelly, Jennifer L.
    Pandya, Chintan
    Friedberg, Jonathan W.
    Mohile, Supriya G.
    BLOOD, 2012, 120 (21)
  • [39] A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma
    Fei Fei Liu
    Meaghan Bartlett
    Samantha Craigie
    PharmacoEconomics - Open, 2024, 8 : 171 - 190
  • [40] A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma
    Liu, Fei Fei
    Bartlett, Meaghan
    Craigie, Samantha
    PHARMACOECONOMICS-OPEN, 2024, 8 (02) : 171 - 190
12345